P34 RKER-065, a novel ActRII ligand trap, counteracted the negative impact of glucocorticoid treatment on bone and muscle

Glucocorticoids are the first-line medications for Duchenne muscular dystrophy. The adverse consequences of glucocorticoid treatment include growth retardation, poor bone health, and muscle atrophy. Transforming growth factor-beta family members, including activin A, activin B and myostatin, are potent negative regulators of musculoskeletal growth. RKER-065 is an investigational, modified type II activin receptor (ActRII) ligand trap designed to bind and inhibit these ligands. The goal of the present study is to determine if RKER-065 can prevent the negative effects of glucocorticoids on bone and muscle.

Source: Neuromuscular Disorders - October 1, 2023 Category: Neurology Authors: G. Zhen, R. Nathan, M. Cahill, C. Materna, F. Fisher, L. Lerner, J. Lachey, J. Seehra Source Type: research